Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy have limited their use. Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) is a potentially life-threatening neurotoxicity that commonly occurs with CAR-T cell therapy. Here we will discuss ICANS, its treatment, possible mechanisms, and potential solutions to this critical limitation of CAR-T cell therapy. As the field of CAR-T cell therapy evolves, improved treatments and methods to circumvent or overcome ICANS are necessary to improve morbidity, mortality, and decrease the cost of CAR-T cell therapy. This serious, life-threatening side effect needs to be studied to better understand its mechanisms and develop treatments and alternative strategies.

Automated summary

CAR-T cell therapy has shown great potential in treating hematological malignancies, but the associated toxicities, such as ICANS, have hindered its widespread use. Understanding the mechanisms and developing solutions for ICANS is crucial for improving the efficacy and safety of CAR-T cell therapy.